Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616841 | 0.85 | HIF1A (0.53) | ADORA3 | |
| SCHEMBL16366033 | 0.83 | PNP (0.77) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL12746240 | 0.83 | PNP (0.77) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL14616839 | 0.80 | ADORA3 (0.61) | PDE4DPDE3AADORA3ADORA1NT5E | |
| SCHEMBL5983227 | 0.78 | PNP (0.72) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL1998269 | 0.78 | PNP (0.72) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL7655065 | 0.78 | PNP (0.72) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL7655056 | 0.78 | PNP (0.72) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5983223 | 0.78 | PNP (0.72) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL17921081 | 0.78 | PNP (0.72) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018010-A1 | POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS | ENZON PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018010-A1 | POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS | VEGFA, MKI67, PCNA | PNP 21/4885LMNA 2053/4885TP53 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.